Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
PHASE1
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1...
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
PHASE1
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, w...
Status
Terminated
Location
University of Alabama at Birmingham - Main /ID# 227071